Romosozumab is effective in patients with variants in LRP5, LRP6, or WNT1
Authors' conclusion
Thus, romosozumab might be a specific treatment for these patients.
Study context
- Population
- Postmenopausal women with heterozygous deleterious or established risk allele variants (ACMG class 2–5) in the LRP5/6 or WNT1 gene27 women · 33 patient-years
- Participants
- 10 / 11 / 12
- Exposure
- Romosozumab vs antiresorptive therapy vs vitamin D and calcium only
- Romosozumab (ROMO)n = 10
- ARn = 11
- NoTn = 12reference
- Outcome
- Lumbar spine areal bone mineral density (aBMD) change
Methodological detailsclinical routine data
- Clinical routine data
Main finding
As reported in the abstract
NoT
−0.12%
± 5.02%
AR
+ 3.97%
± 4.71%
ROMO
+ 15.74%
± 7.63%
ROMO vs AR: P < 0.001 for ROMO vs. AR and vs. NoT · ROMO vs NoT: P < 0.001 for ROMO vs. AR and vs. NoT
Observational data: associations, not effects.
Further findings
| Outcome | ROMO | AR | P value |
|---|---|---|---|
| Bone alkaline phosphatase change · 6 monthsROMO vs AR | + 3.08 ± 2.21 µg/L µg/L | −3.36 ± 8.044 µg/L µg/L | P = 0.026 |
Tibial trabecular bone density and mass (high-resolution peripheral quantitative computed tomography (HR-pQCT))
- Increase with romosozumab
Original publication
Romosozumab is effective in patients with variants in LRP5, LRP6, or WNT1. Osteoporos Int. Published 12 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →